ERRATUM

Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up

D S Olsson, M Buchfelder¹, K Wiendieck¹, N Kremenevskaja¹, B-Å Bengtsson, K-E Jakobsson², M Jarfelt³, G Johannsson and A G Nilsson

Department of Endocrinology, Sahlgrenska University Hospital, Gröna Stråket 8, SE-413 45 Gothenburg, Sweden, ¹Department of Neurosurgery, University of Erlangen-Nuremberg, 91054 Erlangen, Germany, ²Department of Neurosurgery, Sahlgrenska University Hospital, SE-413 45 Gothenburg, Sweden and ³Division of Pediatric Hematology and Oncology, The Queen Silvia Children's Hospital, SE-416 85 Gothenburg, Sweden

The journal apologizes for an error in Fig. 2 of this article published in the *European Journal of Endocrinology* **166** 1061–1068. The GH-treated group and non-GH-treated group were incorrectly identified. The correct figure is published in full below.

European Journal of Endocrinology **167** 135

Figure 2 Cox regression of progression-free survival rates adjusted for initial RT, residual tumour after primary treatment and gender in patients treated with and without GHRT. No association between GHRT and tumour progression was found (HR 0.57; CI for GHRT 0.26–1.3; P value=0.17). The 95% CI for each group are indicated by the red and blue colours (GHRT, GH replacement therapy; RT, radiation therapy).